Oral mucositis (moderate to severe) · Adults with cancer receiving treatment
It is very uncertain whether granulocyte-colony stimulating factor (G-CSF) changes oral mucositis (moderate to severe) compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Interruptions to cancer treatment (radiotherapy breaks longer than two days) · Adults with cancer receiving treatment
Epidermal growth factor (EGF), oral spray showed no clear difference in interruptions to cancer treatment (radiotherapy breaks longer than… compared with placebo; GRADE not reported.
1 finding from 1 review
Speech difficulties (VAS 0-100 mm) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
Pilocarpine led to higher speech difficulties (VAS 0-100 mm) compared with no treatment/placebo; GRADE not reported.
1 finding from 1 review
Normalcy of diet (percutaneous endoscopic gastrostomy) · Adults with cancer receiving treatment
Granulocyte-colony stimulating factor (G-CSF) showed no clear difference in normalcy of diet (percutaneous endoscopic gastrostomy) compared with placebo or no treatment; GRADE not reported.
1 finding from 1 review
Normalcy of diet (total parenteral nutrition) · Adults with cancer receiving treatment
Keratinocyte growth factor (KGF; palifermin or repifermin),… showed no clear difference in normalcy of diet (total parenteral nutrition) compared with placebo; GRADE not reported.
1 finding from 1 review
Normalcy of diet (tube feeding) · Adults with cancer receiving treatment
Granulocyte-macrophage colony-stimulating factor (GM-CSF) showed no clear difference in normalcy of diet (tube feeding) compared with placebo or no treatment; GRADE not reported.
1 finding from 1 review
Number of days of treatment with opioid analgesics · Adults with cancer receiving treatment
Keratinocyte growth factor (KGF; palifermin or repifermin),… showed no clear difference in number of days of treatment with opioid analgesics compared with placebo; GRADE not reported.
1 finding from 1 review
Taste acuity improvement - objective outcome (dichotomous data) · Patients with taste disturbances (dysgeusia/hypogeusia; idiopathic, zinc-deficient, or secondary to chronic renal failure)
It is very uncertain whether zinc supplements (zinc sulphate, zinc gluconate, zinc picolinate,… changes taste acuity improvement - objective outcome (dichotomous data) compared with placebo (very low certainty).
1 finding from 1 review
Dysphagia (WHO grade 3+) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
Biperiden plus pilocarpine showed no clear difference in dysphagia (WHO grade 3+) compared with no treatment; GRADE not reported.
1 finding from 1 review
Normalcy of diet (total parenteral nutrition) · Adults with cancer receiving treatment
Epidermal growth factor (EGF), oral spray showed no clear difference in normalcy of diet (total parenteral nutrition) compared with placebo; GRADE not reported.
1 finding from 1 review
Oral mucositis (severe) · Adults receiving chemotherapy alone for colorectal cancer
Intestinal trefoil factor (ITF), oral spray showed no clear difference in oral mucositis (severe) compared with placebo; GRADE not reported.
1 finding from 1 review
Dry mouth (xerostomia) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
The review found no eligible studies for this question.
1 finding from 1 review
Relief of burning/discomfort (symptom relief; pain intensity) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
1 finding from 1 review
Interventions for treating burning mouth syndrome 2016 · Cochrane All outcomesshort-term (up to 3 months) · benzydamine hydrochloride
SoF9 Topical treatments vs placebo. Symptom relief short-term: insufficient or contradictory evidence regarding benefit of any evaluated topical treatment; 150 participants (4 RCTs); very low. Subgroups: benzydamine (1…
4 studies · 150 participants
Very low
Clinical resolution (oral lesion not completely resolved) · People with a diagnosis of oral leukoplakia
1 finding from 1 review
Malignant transformation (oral cancer development) · People with a diagnosis of oral leukoplakia
It is very uncertain whether topical bleomycin changes oral cancer development compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Relief of burning/discomfort (symptom relief; pain intensity) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
It is very uncertain whether benzodiazepines (topical clonazepam) changes relief of burning/discomfort (symptom relief; pain intensity) compared with placebo (very low certainty).
2 findings from 1 review
Relief of burning/discomfort (symptom relief; pain intensity) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
It is very uncertain whether anticonvulsants (gabapentin 300 mg/day, +/- alpha lipoic acid) changes relief of burning/discomfort (symptom relief; pain intensity) compared with placebo (very low certainty).
1 finding from 1 review
Clinical resolution (oral lesion not completely resolved) · People with a diagnosis of oral leukoplakia
It is very uncertain whether topical bleomycin changes clinical resolution (oral lesion not completely resolved) compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Change in feeling of dryness · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
The review found no eligible studies for this question.
1 finding from 1 review
Change in feeling of dryness · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
The review found no eligible studies for this question.
1 finding from 1 review